共 97 条
[1]
Sparano JA(2018)Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer N Engl J Med 379 111-121
[2]
Gray RJ(2016)70-gene signature as an aid to treatment decisions in early-stage breast cancer N Engl J Med 375 717-729
[3]
Makower DF(2011)Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 Ann Oncol 22 1736-1747
[4]
Cardoso F(2013)Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast Cancer 2013 Ann Oncol 24 2206-2223
[5]
van’t Veer LJ(2012)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials Lancet (London, England) 379 432-444
[6]
Bogaerts J(2001)Optimum anthracycline-based chemotherapy for early breast cancer Lancet Oncol 2 469-474
[7]
Goldhirsch A(1996)Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab J Clin Oncol 14 35-45
[8]
Wood WC(2005)Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5 J Clin Oncol 23 5166-5170
[9]
Coates AS(2006)Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial J Clin Oncol 24 5664-5671
[10]
Goldhirsch A(2008)Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment J Clin Oncol 26 3950-3957